Similar articles

• Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS.

  Limmroth V. Limmroth V. Nat Rev Neurol. 2013 Jan;9(1):8-10. doi: 10.1038/nrneurol.2012.231. Epub 2012 Nov 13. Nat Rev Neurol. 2013. PMID: 23147843 No abstract available.
• Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

  Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Clinical Trial.
• Dimethyl fumarate for relapsing-remitting multiple sclerosis.

  [No authors listed] [No authors listed] Drug Ther Bull. 2014 Sep;52(9):105-8. doi: 10.1136/dtb.2014.9.0279. Drug Ther Bull. 2014. PMID: 25213591
• Contemporary treatment options for relapsing-remitting multiple sclerosis.

  Salhofer-Polanyi S, Leutmezer F. Salhofer-Polanyi S, et al. Drugs Today (Barc). 2014 May;50(5):365-83. doi: 10.1358/dot.2014.50.5.2132741. Drugs Today (Barc). 2014. PMID: 24918837 Review.
• [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].

  Shmidt TE. Shmidt TE. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(11):140-145. doi: 10.17116/jnevro2017117111140-145. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 29265100 Review. Russian.